渗出性年龄相关性黄斑变性治疗延长方案中的退出策略
这项回顾性研究纳入598眼(488例)新生血管性年龄相关性黄斑变性患者,接受抗血管内皮生长因子注射的治疗延长方案,评估预设退出策略的实施结果。17%的眼达到退出标准,平均注射23.7±14.7次、治疗时长4.5±2.5年,13%在平均37±16周后复发。作者认为高退出比例和较低复发率支持预设退出策略的实用性,但部分患者可能需要继续治疗。
要点
- 598眼中17%达到退出标准,平均注射23.7±14.7次,平均治疗4.5±2.5年。
- 12%以最少注射次数达到退出,13%在平均37±16周后复发。
- 复发亚组治疗终止时色素上皮脱离比例显著高于无复发组(77% vs 30%,P=0.0018)。
核心结论
- 较高的退出标准达标比例和相对较低的复发率支持预设退出策略的实用性,但部分患者继续治疗可能是可取的。
研究设计与样本
- 回顾性研究,纳入598眼(488例)接受抗血管内皮生长因子注射治疗延长方案的新生血管性年龄相关性黄斑变性患者。
- 治疗延长方案为间隔延长2周或缩短1周;退出标准定义为连续3次注射间隔16周且表现稳定,之后退出治疗并以3至4个月间隔随访而不治疗。
主要发现
- 全部纳入眼中17%达到退出标准。
- 平均抗血管内皮生长因子注射次数为23.7±14.7次,平均治疗时长为4.5±2.5年。
- 12%以最少注射次数达到退出。
- 13%在平均37±16周后出现复发疾病。
- 复发亚组治疗终止时色素上皮脱离发生率显著高于无复发组(77% vs 30%,P=0.0018),浆液性色素上皮脱离比例也显著更高(31% vs 7%,P=0.0247)。
关键数值与推荐
- 退出标准为连续3次注射间隔16周且表现稳定,退出后以3至4个月间隔随访而不治疗。
临床怎么用
- 作者认为预设退出策略具有实用性,但在部分患者中继续治疗可能是可取的。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the outcome of an exit strategy in a treat-and-extend regimen for neovascular age-related macular degeneration. METHODS: Five hundred and ninety-eight eyes of 488 patients with neovascular age-related macular degeneration receiving intravitreal anti-vascular endothelial growth factor injections according to a treat-and-extend regimen were included in this retrospective study. A treat-and-extend regimen with either interval extension by 2 weeks or shortening by 1 week was used. "Exit criteria" were defined as 3 consecutive injections 16 weeks apart with stable findings after which the patient was exited from treatment and followed up at 3 to 4 monthly intervals without therapy. Best-corrected visual acuity, central retinal thickness at treatment initiation and termination, incidence of recurrence after treatment termination, presence of characteristics in the optical coherence tomography, duration of therapy, number and intervals of injections were analyzed. RESULTS: Seventeen percent of all included eyes met the exit criteria. The mean number of anti-vascular endothelial growth factor injections was 23.7 ± 14.7 with a mean treatment duration of 4.5 ± 2.5 years. Twelve percent reached exit with the minimal number of injections. Thirteen percent had recurrent disease after a mean of 37 ± 16 weeks. In the subgroup with recurrent disease, rate of pigment epithelial detachment at treatment termination was significantly higher than without recurrence (77% vs. 30%, P = 0.0018) with a significant higher proportion of serous pigment epithelial detachment (31% vs. 7%, P = 0.0247). CONCLUSION: The high percentage of patients meeting the exit criteria and the relatively low incidence of recurrences underline the usefulness of a predefined exit strategy. However, in a subgroup of patients, continuation of therapy may be advisable.
引用
- Arendt P, Yu S, Munk MR, et al. EXIT STRATEGY IN A TREAT-AND-EXTEND REGIMEN FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION. Retina. 2019. PMID: 29135888. doi:10.1097/IAE.0000000000001923
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。